Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The revision version has been updated from v3.5.4 to v3.5.5, indicating a behind-the-scenes platform/template update.
    Difference
    0.0%
    Check dated 2026-06-05T20:30:32.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    New related topic navigation entries were added for Melanoma and MedlinePlus Genetics, expanding access to related informational resources on the page.
    Difference
    0.1%
    Check dated 2026-05-29T23:14:59.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The related topics section has been cleaned to remove Melanoma and MedlinePlus Genetics entries, along with the related topics label, reducing the visible navigation to those topics.
    Difference
    0.1%
    Check dated 2026-05-22T18:47:51.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    Added 'Melanoma' as a related topic and included 'MedlinePlus Genetics' as related topics, expanding cross-referencing and searchability for the page. The page revision was updated to v3.5.4, indicating a minor metadata update.
    Difference
    0.2%
    Check dated 2026-05-15T15:24:43.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The page’s related topics section now lists Melanoma and MedlinePlus Genetics. These additions broaden navigational links to melanoma-related information and genetics resources on the page.
    Difference
    0.1%
    Check dated 2026-05-08T11:55:30.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The follow-up visit cadence for participants is now specified: 2-day follow-up visits occur every 1-3 months for the first year, then every 6 months. This clarifies the post-treatment monitoring timeline within the Study Plan.
    Difference
    0.2%
    Check dated 2026-05-01T09:23:36.000Z thumbnail image

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.